HBV Epitopic Peptides for CTL Response Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Hepatitis B virus (HBV) infection are inadequate in eliminating the virus from chronically infected individuals, as they fail to induce robust and sustained T cell responses necessary for permanent clearance.
Innovation Solution
Development of immunogens comprising novel epitopic peptide sequences associated with HLA-A2 and HLA-A24 molecules, identified through immunoproteomic approaches, which are used to stimulate cytotoxic T lymphocyte responses against HBV-infected cells, potentially leading to the development of a universally immunogenic vaccine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional prophylactic vaccines and anti-HBV therapies are used, then prevention of HBV infection is achieved, but elimination of HBV from chronically infected individuals is not achieved
Solution Approach 1:
The patent segments the HBV antigens into multiple specific epitopic peptides (such as those from surface, core, and polymerase proteins) that can be individually identified and combined. This segmentation allows for the creation of tailored therapeutic vaccines that target specific viral proteins, thereby improving the reliability of virus clearance in chronically infected individuals while maintaining adaptability through selective epitope combinations.
Solution Approach 2:
The patent changes the parameter of antigen presentation by identifying and utilizing specific MHC class I-associated epitopic peptides with defined amino acid sequences. This parameter change from whole proteins to specific peptide epitopes enhances the immunogenicity and T cell recognition, thereby improving therapeutic efficacy for HBV elimination while adapting to different MHC types through epitope selection.
2Reliability
If robust and sustained T cell responses are induced, then permanent clearance of HBV is achieved, but current therapies fail to achieve this response
Solution Approach 1:
The patent performs preliminary identification and characterization of MHC class I-associated epitopic peptides from HBV proteins before vaccine formulation. This preliminary action includes using immunoproteomic approaches to identify naturally processed and presented peptides, which ensures that the resulting therapeutic vaccine will induce robust T cell responses. This upfront work reduces the complexity of subsequent vaccine development and manufacturing.
Solution Approach 2:
The patent creates synthetic copies of the identified epitopic peptide sequences for use in therapeutic vaccines. These synthetic peptide copies can be manufactured with high precision and consistency, ensuring robust T cell responses while simplifying the manufacturing process compared to using whole proteins or complex antigen preparations.
3Adaptability or versatility
If multiple epitopic peptides from different HBV proteins are combined, then universally immunogenic vaccine is achieved, but vaccine complexity increases
Solution Approach 1:
The patent identifies epitopic peptides from multiple HBV proteins (surface, core, polymerase, precore/core) that can be combined to create a universally immunogenic vaccine. These peptides are selected based on their ability to bind to MHC class I molecules and induce T cell responses, providing multi-functionality that targets different viral proteins and enhances overall immunogenicity while maintaining a manageable vaccine composition through rational epitope selection.
Data Source
AI summary
The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.